Analystreport

Xeris Pharmaceuticals Inc (NASDAQ: XERS) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $18.00 price target on the stock.

Xeris Biopharma Holdings, Inc.  (XERS) 
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am Check Earnings Report